MOG

TRE-515 Appears to Block Immune Cell Attacks in Mouse Study

An experimental oral therapy called TRE-515 significantly reduced disease severity and the growth of the abnormal immune cells that drive multiple sclerosisĀ (MS) in two mouse models of the disease, a study found. Notably, the efficacy of Trethera Corp.ā€™s potential treatment, administered either in a preventive or therapeutic…

1st RRMS Patient Dosed in Phase 1/2 Trial of Immunotherapy IMCY-0141

A Phase 1/2 clinical trial evaluating Imcyseā€™s experimental therapy IMCY-0141 in people with relapsing-remitting multiple sclerosisĀ (RRMS) has dosed its first patient. The trial, called IMCY-MS-001, is expected to enroll nearly 150 adults with RRMS;Ā sites were not disclosed in a release by the Belgium-based company. Interim results may be available…

#MSParis2017 – MOG-associated Demyelination Can Be Treated with Steroids, but Maintenance Is Required

People with aĀ demyelinating disease associated withĀ antibodies against a myelin oligodendrocyte glycoprotein (MOG), most often develop episodes of optic neuritis (inflammation of the optic nerve) that can be treated with corticosteroids, according to data presented today at theĀ 7th Joint ECTRIMS-ACTRIMS MeetingĀ from Oct. 25-28 in Paris. MOG antibody-associated demyelination is a…